Annual Report

Overview

The report is 3D Medicines' first ESG disclosure and covers the Group's 2022 sustainability practices and achievements. It highlights Envafolimab commercialization, including RMB567 million in sales and broad hospital and pharmacy coverage. The report also establishes Board-led ESG oversight and reports total GHG emissions of 3,746.82 tCO2e for 2022.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Level
Standard
Scope
Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services